NCT05599347View on ClinicalTrials.gov

Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Crohn's Disease RelapseBiological Substance; Adverse Effect
Interventions
DRUG

Azithromycin Pill

Tablet - 500 mg azithromycin (as dihydrate)

OTHER

Placebo

Placebo tablet identical in shape and appearance to the azithromycin tablet used in the treatment arm

Trial Locations (9)

Unknown

RECRUITING

Soroka University Medical Center, Beersheba

RECRUITING

Bnei Zion, Haifa

RECRUITING

Carmel Medical Center, Haifa

RECRUITING

Rambam Health Care Campus, Haifa

RECRUITING

Wolfson Medical Center, Holon

RECRUITING

Hadassah Medical Center, Jerusalem

RECRUITING

Shaare Zedek, Jerusalem

RECRUITING

Zvulun, Kiryat Bialik

RECRUITING

Rabin Medical Center, Petah Tikva

All Listed Sponsors
lead

Rambam Health Care Campus

OTHER